Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Cash from Operations for 6 consecutive years, with 46498000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 58.2% to 46498000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 183496000.0, a 61.85% decrease, with the full-year FY2024 number at 134585000.0, down 77.57% from a year prior.
  • Cash from Operations was 46498000.0 for Q3 2025 at 4D Molecular Therapeutics, down from 43377000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1171000.0 in Q3 2023 to a low of 47758000.0 in Q1 2025.
  • A 5-year average of 26517315.79 and a median of 23550000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 94.43% in 2023, then tumbled 2409.91% in 2024.
  • 4D Molecular Therapeutics' Cash from Operations stood at 21836000.0 in 2021, then fell by 1.73% to 22214000.0 in 2022, then decreased by 10.97% to 24650000.0 in 2023, then tumbled by 86.06% to 45863000.0 in 2024, then dropped by 1.38% to 46498000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Cash from Operations are 46498000.0 (Q3 2025), 43377000.0 (Q2 2025), and 47758000.0 (Q1 2025).